YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Biogen Applies for FDA Approval of Hemophilia Med


January 4, 2013 | Biogen Idec has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of a treatment for hemophilia B. The regulatory submission was based on results from B-LONG, the largest registrational phase 3 clinical study in hemophilia B to date. Biogen Idec Press Release 
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.